Humatin Shortage Update: What Patients Need to Know in 2026

Humatin (paromomycin sulfate) is a specialty antiparasitic antibiotic that is notoriously difficult to find at retail pharmacies across the United States. If you've been trying to fill a Humatin prescription, here's the most current information on its availability status, why it's scarce, and what steps you can take as a patient in 2026.

Is Humatin Officially in a Drug Shortage?

As of 2026, Humatin (paromomycin) is not listed on the FDA's official Current Drug Shortages database. This database tracks supply disruptions caused by manufacturing problems, raw material shortages, or production failures. Humatin's availability issues are different in nature — they stem from low demand, high cost, and limited pharmacy distribution rather than a manufacturing supply crisis.

However, patients and providers consistently report difficulty obtaining Humatin at standard retail pharmacies. This creates a "de facto" access challenge that doesn't show up in official shortage data but has very real consequences for the patients who need this drug.

The Generic Discontinuation: A Key Driver of Limited Access

One of the most significant developments affecting Humatin access was the discontinuation of generic paromomycin sulfate capsules. When generics are available, competition drives prices down and expands the number of pharmacies that stock a drug. Without a generic, patients are left with only the brand-name Humatin from Waylis Therapeutics — a product that retails for upwards of $3,000–$6,000 for a single treatment course.

This is not an isolated pattern. A 2026 paper published in Open Forum Infectious Diseases highlighted the "exorbitant cost of antiparasitic drugs in the United States," noting that national patient assistance programs like Humatin TotalCare aim to improve access, but strict eligibility criteria and complex enrollment processes are often barriers. The paper called for reform of how niche antiparasitic drugs are priced and distributed in the U.S.

Current Availability Status in 2026

Here is a snapshot of what we know about Humatin availability in 2026:

• Brand-name Humatin (250 mg capsules): Commercially available in the U.S., manufactured by Waylis Therapeutics. Not in an FDA-declared shortage.
• Generic paromomycin sulfate: Discontinued. Not available through standard pharmacy channels.
• Retail pharmacy availability: Very limited. Most major retail chains (CVS, Walgreens, Rite Aid) do not stock Humatin routinely.
• Specialty/hospital pharmacies: Best source — these pharmacies can stock or order Humatin within a few business days.
• Insurance coverage: Variable. Prior authorization is often required. Some plans do not cover Humatin at all, requiring use of the manufacturer's patient assistance program.

Who Is Most Affected by Humatin's Limited Availability?

The patients most affected by Humatin's limited accessibility tend to be:

• Patients newly diagnosed with intestinal amebiasis who may be unfamiliar with specialty pharmacy systems
• Immigrants and international travelers who may have limited English proficiency or unfamiliarity with U.S. pharmacy navigation
• Uninsured or underinsured patients who cannot afford the $3,000+ retail price without assistance
• Pregnant patients with giardiasis for whom paromomycin is the safest treatment option
• Patients in rural areas with fewer specialty pharmacy options

What You Can Do as a Patient

If you need Humatin in 2026, take these steps:

1. Use medfinder.com to search for pharmacies that have Humatin — this service calls pharmacies on your behalf so you don't have to.
2. Contact Waylis Therapeutics at 844-200-7910 to ask about the Humatin TotalCare patient assistance program and pharmacy referrals.
3. Ask your prescriber to send your prescription to a specialty or hospital pharmacy rather than a retail chain.
4. If your insurance requires prior authorization, ask your doctor's office to start the process immediately — don't wait until you've confirmed stock.
5. If Humatin is truly inaccessible, discuss alternatives with your doctor.

The Bigger Picture: Niche Antiparasitic Access in America

Humatin's availability challenges are emblematic of a broader problem with specialty antiparasitic drugs in the U.S. These medications treat infections that primarily affect immigrant communities, travelers, and immunocompromised patients — groups that often have less political and market power. Researchers and advocates have called for pooled purchasing agreements, expedited generic pathways, and streamlined import of WHO-prequalified generics to address this gap. Until systemic change happens, patients navigating this system need every tool available.